# A Study of Inclisiran in Participants With Homozygous Familial Hypercholesterolemia (HoFH)

> **NCT03851705** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 56 (actual)

## Conditions studied

- Homozygous Familial Hypercholesterolemia

## Interventions

- **DRUG:** Inclisiran Sodium for injection
- **DRUG:** Placebo
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT03851705
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-06
- **Primary completion:** 2020-03-02
- **Final completion:** 2021-09-09
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2023-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03851705

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03851705, "A Study of Inclisiran in Participants With Homozygous Familial Hypercholesterolemia (HoFH)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03851705. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*